Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Aveo Pharmaceuticals stock price, quote, forecast and news

AVEO
US0535883070
A2P0CL

Price

15.00
Today +/-
+0
Today %
+0 %
P

Aveo Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aveo Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aveo Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aveo Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aveo Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aveo Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aveo Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aveo Pharmaceuticals’s growth potential.

Aveo Pharmaceuticals Revenue, EBIT and net profit per share

DateAveo Pharmaceuticals RevenueAveo Pharmaceuticals EBITAveo Pharmaceuticals Net Income
2026e355.73 M undefined211.53 M undefined115.32 M undefined
2025e305.22 M undefined109.61 M undefined72 M undefined
2024e233.91 M undefined58.33 M undefined45.86 M undefined
2023e184.75 M undefined26.61 M undefined19.03 M undefined
2022e114.29 M undefined-19.18 M undefined-23.99 M undefined
202142.3 M undefined-49.55 M undefined-53.34 M undefined
20206 M undefined-38.9 M undefined-35.6 M undefined
201928.8 M undefined-400,000 undefined9.4 M undefined
20185.4 M undefined-26.1 M undefined-5.3 M undefined
20177.6 M undefined-26.7 M undefined-65 M undefined
20162.5 M undefined-29.4 M undefined-26.9 M undefined
201519 M undefined-8.1 M undefined-15 M undefined
201418.1 M undefined-38.7 M undefined-52.7 M undefined
20131.3 M undefined-95.9 M undefined-107 M undefined
201219.3 M undefined-109 M undefined-114.4 M undefined
2011164.8 M undefined33.9 M undefined30.6 M undefined
201044.7 M undefined-56.4 M undefined-58.8 M undefined
200920.7 M undefined-41.2 M undefined-44.1 M undefined
200819.7 M undefined-31.4 M undefined-32.5 M undefined
200711 M undefined-24.7 M undefined-25 M undefined
20067.8 M undefined-24.2 M undefined-24.9 M undefined
20056.2 M undefined-16.3 M undefined-16.1 M undefined

Aveo Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200520062007200820092010201120122013201420152016201720182019202020212022e2023e2024e2025e2026e
6711192044164191181927528642114184233305355
-16.6757.1472.735.26120.00272.73-88.41-94.741,700.005.56-89.47250.00-28.57460.00-78.57600.00171.4361.4026.6330.9016.39
----------------88.10-----
00000000000000003700000
-16-24-24-31-41-5633-109-95-38-8-29-26-260-38-49-192658109211
-266.67-342.86-218.18-163.16-205.00-127.2720.12-573.68-9,500.00-211.11-42.11-1,450.00-371.43-520.00--633.33-116.67-16.6714.1324.8935.7459.44
-16-24-25-32-44-5830-114-107-52-15-26-65-59-35-53-23194572115
-50.004.1728.0037.5031.82-151.72-480.00-6.14-51.40-71.1573.33150.00-92.31-280.00-488.8951.43-56.60-182.61136.8460.0059.72
0.20.20.20.20.22.64.14.35.15.25.66.910.612.115.421.432.6600000
----------------------
Details

Keystats

ⓘ

Revenue and Growth

The Aveo Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Aveo Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Aveo Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Aveo Pharmaceuticals's financial health and stability.

Assets

Aveo Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Aveo Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Aveo Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Aveo Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2006200720082009201020112012201320142015201620172018201920202021
-24-24-32-44-5830-114-107-52-15-26-65-59-35-53
1111112369000000
0000000000000000
114-6290-16-413-23-908-2-30-10
002351010515-2-337-17-8-26
1112233221121112
0000000000000000
-21-8-35-9-5126-105-84-54-18-31-19-25-2-37-57
00-1-1-1-2-9-3-120000000
18-39283-90-1441351254-60-1018-1717-16
19-39295-88-1411451567-60-1018-1718-16
0000000000000000
12-416-1401-72-11550-3-125
057033138115154010152416305358
12526311421153471-1202915265282
---10.00------1.00-------
0000000000000000
1040240-232-251-25-11095318
-22.05-8.98-36.66-11.7-53.5223.82-115.68-88.07-67.19-18.25-31.08-19.16-25.03-2.92-38.34-57.26
0000000000000000

Aveo Pharmaceuticals stock margins

The Aveo Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aveo Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aveo Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aveo Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Aveo Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aveo Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aveo Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aveo Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aveo Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aveo Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aveo Pharmaceuticals Margin History

Aveo Pharmaceuticals Gross marginAveo Pharmaceuticals Profit marginAveo Pharmaceuticals EBIT marginAveo Pharmaceuticals Profit margin
2026e88.8 %59.46 %32.42 %
2025e88.8 %35.91 %23.59 %
2024e88.8 %24.94 %19.61 %
2023e88.8 %14.4 %10.3 %
2022e88.8 %-16.78 %-20.99 %
202188.8 %-117.16 %-126.12 %
202088.8 %-648.33 %-593.33 %
201988.8 %-1.39 %32.64 %
201888.8 %-483.33 %-98.15 %
201788.8 %-351.32 %-855.26 %
201688.8 %-1,176 %-1,076 %
201588.8 %-42.63 %-78.95 %
201488.8 %-213.81 %-291.16 %
201388.8 %-7,376.92 %-8,230.77 %
201288.8 %-564.77 %-592.75 %
201188.8 %20.57 %18.57 %
201088.8 %-126.17 %-131.54 %
200988.8 %-199.03 %-213.04 %
200888.8 %-159.39 %-164.97 %
200788.8 %-224.55 %-227.27 %
200688.8 %-310.26 %-319.23 %
200588.8 %-262.9 %-259.68 %

Aveo Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Aveo Pharmaceuticals earnings per share therefore indicates how much revenue Aveo Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aveo Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aveo Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aveo Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aveo Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aveo Pharmaceuticals Revenue, EBIT and net profit per share

DateAveo Pharmaceuticals Sales per ShareAveo Pharmaceuticals EBIT per shareAveo Pharmaceuticals Earnings per Share
2026e10.23 undefined0 undefined3.32 undefined
2025e8.78 undefined0 undefined2.07 undefined
2024e6.73 undefined0 undefined1.32 undefined
2023e5.31 undefined0 undefined0.55 undefined
2022e3.29 undefined0 undefined-0.69 undefined
20211.29 undefined-1.52 undefined-1.63 undefined
20200.28 undefined-1.82 undefined-1.66 undefined
20191.87 undefined-0.03 undefined0.61 undefined
20180.45 undefined-2.16 undefined-0.44 undefined
20170.72 undefined-2.52 undefined-6.13 undefined
20160.36 undefined-4.26 undefined-3.9 undefined
20153.39 undefined-1.45 undefined-2.68 undefined
20143.48 undefined-7.44 undefined-10.13 undefined
20130.25 undefined-18.8 undefined-20.98 undefined
20124.49 undefined-25.35 undefined-26.6 undefined
201140.2 undefined8.27 undefined7.46 undefined
201017.19 undefined-21.69 undefined-22.62 undefined
2009103.5 undefined-206 undefined-220.5 undefined
200898.5 undefined-157 undefined-162.5 undefined
200755 undefined-123.5 undefined-125 undefined
200639 undefined-121 undefined-124.5 undefined
200531 undefined-81.5 undefined-80.5 undefined

Aveo Pharmaceuticals business model

Aveo Pharmaceuticals Inc. is a bio-pharmaceutical company focused on the development of new therapies for cancer patients. The company was founded in 2001 in Cambridge, Massachusetts and is listed on the NASDAQ stock exchange under the ticker symbol AVEO. The history of Aveo Pharmaceuticals began with the discovery of a growth factor responsible for the formation of blood vessels in tumors. In collaboration with Harvard Medical School and the Dana-Farber Cancer Institute, the company developed a new drug called Tivozanib, which can block this growth factor. Tivozanib has been tested as a potential treatment for various types of cancer, including kidney cancer, breast cancer, and lung cancer, and is currently in various stages of development. Aveo Pharmaceuticals employs a collaborative business model to involve scientists and researchers in the development of new therapies. The company works together with leading academic institutions and bio-pharmaceutical companies to accelerate and improve the drug development process. Aveo Pharmaceuticals is divided into different divisions that focus on the development of therapies for different types of cancer. These divisions include oncology, which focuses on the development of therapies for solid tumors, as well as hematology, which focuses on the development of therapies for blood cancer. Aveo Pharmaceuticals also has a pipeline of products in various stages of development. These products include both novel drugs and therapies that are already on the market. One of Aveo Pharmaceuticals' most promising products is the drug Tivozanib. Tivozanib is a kinase inhibitor specifically designed for the treatment of kidney cancer. The drug has proven to be effective in clinical trials and could soon be approved by the U.S. Food and Drug Administration (FDA). Tivozanib could improve both the quality of life and the survival rate of kidney cancer patients. Another promising drug from Aveo Pharmaceuticals is Ficlatuzumab, a drug specifically designed for the treatment of solid tumors. Ficlatuzumab targets the hepatocyte growth factor receptor (HGFR), which is overexpressed in various types of cancer such as breast cancer, lung cancer, and pancreatic cancer. The drug is currently in clinical trials and has the potential to become a new treatment option for cancer patients. Over the years, Aveo Pharmaceuticals has received numerous awards and recognitions, including being recognized as one of the "50 Most Innovative Companies in the World" by Technology Review and being included in the "Forbes 200 Best Small Companies in America" ranking. In summary, Aveo Pharmaceuticals is an innovative bio-pharmaceutical company focused on the development of vital therapies for cancer patients. Aveo Pharmaceuticals' collaborative business model has enabled the company to work closely with leading academic institutions and bio-pharmaceutical companies to develop new drugs that could improve the lives of cancer patients. With Tivozanib and Ficlatuzumab, Aveo Pharmaceuticals has two promising drugs in the pipeline that have the potential to change the face of cancer treatment. Aveo Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Aveo Pharmaceuticals SWOT Analysis

Strengths

Aveo Pharmaceuticals Inc possesses several strengths that contribute to its success:

  • Strong research and development capabilities
  • A broad portfolio of innovative drugs and therapies
  • A dedicated and skilled workforce
  • Established partnerships with key industry players
  • Strong financial position and access to capital

Weaknesses

Despite its strengths, Aveo Pharmaceuticals Inc also has weaknesses that need to be addressed:

  • Dependence on a limited number of product lines
  • Relatively small market share compared to larger pharmaceutical companies
  • Limited international presence
  • Vulnerability to changes in regulatory environment
  • Potential for high research and development costs

Opportunities

Aveo Pharmaceuticals Inc can capitalize on the following opportunities:

  • Increasing demand for innovative therapies and personalized medicine
  • Growing aging population and prevalence of chronic diseases
  • Expanding into emerging markets with high growth potential
  • Potential collaborations with academic institutions and research organizations
  • Advancements in technology and data analytics for drug discovery

Threats

Aveo Pharmaceuticals Inc needs to be aware of the following threats in the industry:

  • Intense competition from larger pharmaceutical companies
  • Stringent regulations and compliance requirements
  • Risks associated with clinical trial failures
  • Price pressures and reimbursement challenges in healthcare systems
  • Intellectual property infringement and generic drug competition

Aveo Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Aveo Pharmaceuticals shares outstanding

The number of shares was Aveo Pharmaceuticals in 2023 — This indicates how many shares 32.661 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aveo Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aveo Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aveo Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aveo Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aveo Pharmaceuticals Stock splits

In Aveo Pharmaceuticals's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Aveo Pharmaceuticals.

Aveo Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2022-0.18 -0.09  (49.86 %)2022 Q3
6/30/2022-0.29 -0.24  (15.97 %)2022 Q2
3/31/2022-0.25 -0.3  (-18.58 %)2022 Q1
12/31/2021-0.29 -0.21  (28.38 %)2021 Q4
9/30/2021-0.37 -0.3  (18.85 %)2021 Q3
6/30/2021-0.46 -0.4  (12.85 %)2021 Q2
3/31/2021-0.56 -0.81  (-45.03 %)2021 Q1
12/31/2020-0.39 -0.44  (-13.52 %)2020 Q4
9/30/2020-0.24 -0.33  (-34.8 %)2020 Q3
6/30/2020-0.52 -0.42  (18.73 %)2020 Q2
1
2
3
4
5
...
6

Aveo Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
4.79 % Rubric Capital Management LP1,664,667740,7829/30/2022
4.34 % The Vanguard Group, Inc.1,507,9556,6389/30/2022
2.81 % AIGH Capital Management, LLC.975,993-1,763,26210/16/2022
1.97 % Worth Venture Partners, LLC685,026-31,4109/30/2022
1.89 % J. Goldman & Co., L.P.656,161-662,2609/30/2022
1.87 % EcoR1 Capital, LLC650,4893,0009/30/2022
1.47 % BlackRock Institutional Trust Company, N.A.510,841-8,1049/30/2022
1.46 % IndexIQ Advisors LLC508,822-4,67812/31/2022
1.10 % EAM Investors, LLC380,691194,4899/30/2022
1.06 % GlobeFlex Capital, L.P.368,520368,5209/30/2022
1
2
3
4
5
...
10

Aveo Pharmaceuticals Executives and Management Board

Mr. Michael Bailey56
Aveo Pharmaceuticals President, Chief Executive Officer, Director (since 2010)
Compensation 2.94 M
Mr. Michael Ferraresso48
Aveo Pharmaceuticals Chief Commercial Officer
Compensation 1.25 M
Mr. Erick Lucera54
Aveo Pharmaceuticals Chief Financial Officer
Compensation 1.24 M
Mr. Kenneth Bate71
Aveo Pharmaceuticals Independent Chairman of the Board
Compensation 158,734
Dr. Corinne Epperly44
Aveo Pharmaceuticals Independent Director
Compensation 148,248
1
2
3

Most common questions regarding Aveo Pharmaceuticals

What values and corporate philosophy does Aveo Pharmaceuticals represent?

Aveo Pharmaceuticals Inc. is committed to bringing innovative therapies to patients in need. With a strong corporate philosophy centered around advancing the treatment landscape, Aveo strives to develop targeted medicines addressing unmet medical needs. The company's dedication to improving patient outcomes is reflected in its focus on precision medicine and personalized therapies. Aveo prioritizes collaboration and actively seeks strategic partnerships to accelerate the development and commercialization of its novel drug candidates. By maintaining a patient-centric approach and embracing scientific excellence, Aveo Pharmaceuticals Inc. positions itself as a leader in the biopharmaceutical industry.

In which countries and regions is Aveo Pharmaceuticals primarily present?

Aveo Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Aveo Pharmaceuticals achieved?

Aveo Pharmaceuticals Inc has achieved several significant milestones in its journey. One of the major accomplishments includes the approval of their lead product, Tivozanib, by the U.S. Food and Drug Administration (FDA) for advanced renal cell carcinoma patients. Additionally, Aveo Pharmaceuticals Inc has successfully partnered with multinational companies, such as EUSA Pharma and Biodesix, to commercialize and expand the reach of their innovative therapies. The company has also made remarkable progress in their clinical development program, further demonstrating the potential of their pipeline candidates. Aveo Pharmaceuticals Inc continues to thrive by consistently advancing its research and development efforts to bring novel solutions to patients in need.

What is the history and background of the company Aveo Pharmaceuticals?

Aveo Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of targeted cancer therapies. Founded in 2002 and headquartered in Cambridge, Massachusetts, Aveo has a rich history in the field of oncology. The company has been dedicated to discovering and developing innovative therapies to improve the lives of cancer patients. Aveo has collaborated with various partners and achieved significant milestones in its journey. With a commitment to advancing precision medicine, Aveo continues to make strides towards the development of novel treatment options for cancer patients worldwide.

Who are the main competitors of Aveo Pharmaceuticals in the market?

The main competitors of Aveo Pharmaceuticals Inc in the market are Bristol-Myers Squibb Company, Novartis AG, and Pfizer Inc.

In which industries is Aveo Pharmaceuticals primarily active?

Aveo Pharmaceuticals Inc is primarily active in the biopharmaceutical industry.

What is the business model of Aveo Pharmaceuticals?

Aveo Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of targeted cancer therapies. Their business model revolves around researching, discovering, and advancing innovative medicines that address unmet medical needs for cancer patients. Aveo Pharmaceuticals Inc seeks to develop therapies that target and inhibit specific pathways involved in tumor growth and multiplication. By identifying and developing potential treatments, Aveo Pharmaceuticals aims to improve patient outcomes and provide better options for cancer treatment.

What is the P/E ratio of Aveo Pharmaceuticals 2024?

The Aveo Pharmaceuticals P/E ratio is 10.68.

What is the P/S ratio of Aveo Pharmaceuticals 2024?

The Aveo Pharmaceuticals P/S ratio is 2.09.

What is the AlleAktien quality score of Aveo Pharmaceuticals?

The AlleAktien quality score for Aveo Pharmaceuticals is 4/10.

What is the revenue of Aveo Pharmaceuticals 2024?

The expected Aveo Pharmaceuticals revenue is 233.91 M USD.

How high is the profit of Aveo Pharmaceuticals 2024?

The expected Aveo Pharmaceuticals profit is 45.86 M USD.

What is the business model of Aveo Pharmaceuticals

Aveo Pharmaceuticals Inc is a biopharmaceutical company focused on developing cancer medications. The company is based in Cambridge, Massachusetts and is led by a team of experienced professionals from the pharmaceutical industry.

What is the Aveo Pharmaceuticals dividend?

Aveo Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Aveo Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Aveo Pharmaceuticals or the company does not pay out a dividend.

What is the Aveo Pharmaceuticals ISIN?

The ISIN of Aveo Pharmaceuticals is US0535883070.

What is the Aveo Pharmaceuticals WKN?

The WKN of Aveo Pharmaceuticals is A2P0CL.

What is the Aveo Pharmaceuticals ticker?

The ticker of Aveo Pharmaceuticals is AVEO.

How much dividend does Aveo Pharmaceuticals pay?

Over the past 12 months, Aveo Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aveo Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aveo Pharmaceuticals?

The current dividend yield of Aveo Pharmaceuticals is .

When does Aveo Pharmaceuticals pay dividends?

Aveo Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aveo Pharmaceuticals?

Aveo Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aveo Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aveo Pharmaceuticals located?

Aveo Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aveo Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aveo Pharmaceuticals from 8/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/2/2024.

When did Aveo Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/2/2024.

What was the dividend of Aveo Pharmaceuticals in the year 2023?

In the year 2023, Aveo Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aveo Pharmaceuticals pay out the dividend?

The dividends of Aveo Pharmaceuticals are distributed in USD.

All fundamentals about Aveo Pharmaceuticals

Our stock analysis for Aveo Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aveo Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.